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Abstract
This report by a group of UK retina specialists and health professionals considers best practice recommendations for the
management of sight-threatening neovascular age-related macular degeneration (nAMD), based on collective experience and
expertise in routine clinical practice. The authors provide an update for ophthalmologists, allied healthcare professionals and
commissioners on practice principles for optimal patient care and service provision standards. Reﬁnement of care pathways
for nAMD has improved access to intravitreal anti-vascular endothelial growth factor therapy but there are still variations in
care and reported outcomes between clinic centres. Innovative organisational models of service provision allow providers to
better match capacity with increasing demand. The authors review the recent NICE guideline for diagnosis and management
of AMD, considerations for switching therapies and stopping treatment and need for regular monitoring of non-affected
fellow eyes in patients with unilateral nAMD. Actions for delivery of high-quality care and to improve long-term patient
outcomes are discussed. Local pathways need to detail nAMD target time to treat, maintenance of review intervals to ensure
proactive treatment regimens are delivered on time and appropriate discharge for patients deemed low risk or no longer
beneﬁting from treatment. Actual visual acuity outcomes achieved and maintenance of the level of vision when disease
stability is achieved are considered good measures for judging the quality of care in the treatment of patients with nAMD.
Robust community referral pathways must be in place for suspected reactivation of choroidal neovascularisation and rapid
referral for second eye involvement. Practical considerations for intravitreal injection therapy are outlined.
Introduction
Over the past decade, intravitreal anti-vascular endothelial
growth factor (anti-VEGF) therapy has become established
as the standard of care for the treatment of neovascular age-
related macular degeneration (nAMD), supported by evi-
dence from randomised clinical trials as well as routine
clinical practice demonstrating efﬁcacy in preventing visual
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loss and improving vision [1–4]. Wider access to effective
treatment has been accompanied by reported decline in the
incidence of blindness and visual impairment from age-
related macular degeneration (AMD) [5–8]. A study of
treatment outcomes reported annual decreases in the inci-
dence of blindness attributable to nAMD in southeast
Scotland following the introduction of intravitreal anti-
VEGF therapy, from a peak of 9.1 cases per 100,000
population in 2006 declining to 4.8 cases per 100,000 in
2011, representing a 47% decrease over 5 years [8]. How-
ever, AMD remains by far the leading cause of certiﬁcations
for sight impairment in England and Wales [9].
Age-speciﬁc prevalence of nAMD in the UK population
is estimated at 1.2% in those aged ≥50 years, increasing to
2.5% in those aged ≥65 years and 6.3% in those aged ≥80
years [10]. The number of prevalent cases of late AMD is
expected to rise steadily due to population ageing. The
annual number of incident cases of nAMD in the UK is
estimated at 39,700, a ﬁgure that may not reﬂect the number
in need of or likely to beneﬁt from treatment [10]. Figure 1
shows the estimated annual incidence of nAMD per 1000
and Fig. 2 shows the estimated annual number of new cases
of nAMD in the UK population aged ≥50 years [10].
Neovascular AMD is a chronic lifelong condition
requiring ongoing treatment with regular follow-up and
monitoring to control exudative disease activity. An Action
on AMD expert group in 2012 previously drew attention to
limited or inadequate clinic capacity in the National Health
Service (NHS) hospital eye service (HES) that threatened
‘optimal care and access to potentially sight-saving treat-
ment’ for patients with nAMD [11]. As individual nAMD
providers differ in structure, size and patient population, as
well as in speciﬁc service limitations, a ﬂexible approach to
service redesign was and remains recommended.
A follow-up Action on nAMD roundtable meeting,
involving a group of UK ophthalmic retina specialists and
health professionals, was held in March 2018 to review
earlier recommendations and progress achieved within the
HES, with the aim of providing an informed update on
issues of current clinical relevance. The authors review
different service delivery options for addressing increasing
demand and present practical suggestions for maximising
capacity. Recent guideline advice for diagnosis and man-
agement of AMD from the National Institute for Health and
Care Excellence (NICE) [12] is reviewed and practice
considerations for switching therapies, stopping treatment
and monitoring of non-affected fellow eyes discussed. The
practicalities of intravitreal injection delivery are also
revisited. For quick reference, key points and recommen-
dations are summarised in Tables 1 and 2.
Action on AMD group: practice trends and
reappraisal of service provision
Practice trends in the clinical management of nAMD
The ophthalmology specialty has experienced considerable
growth in outpatient attendances for treatment initiation and
ongoing management of nAMD. For example, hospital
activity in England for people with a primary diagnosis of
AMD was less than 10,000 visits in 2005–2006 compared
with over 75,000 visits in 2013–2014 [12].
Medical retina services across the UK NHS have
expanded and evolved to meet the large treatment burden
and increasing demand for intravitreal injection therapy.
Over the past 8 years, there has been progressive investment
to support reﬁnement of practice protocols and care path-
ways to ensure provision and delivery of a high standard of
care for people with nAMD and other retinal vascular
diseases.
Non-invasive spectral domain optical coherence tomo-
graphy (SD-OCT) is increasingly adopted as a core tool for
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Fig. 1 Estimated annual incidence of nAMD per 1000 in the UK
population aged ≥50 years. Data from Owen et al. (Web Table 2) [10].
Available at: http://openaccess.sgul.ac.uk/1994/1/bjophthalmol-2011-
301109-s3.pdf
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Fig. 2 Estimated annual number of new cases of nAMD (‘000s) in the
UK population aged ≥50 years. Data from Owen et al. (Web Table 2)
[10]. Available at: http://openaccess.sgul.ac.uk/1994/1/bjophthalmol%
2D2011%2D301109%2Ds3.pdf
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diagnosis and follow-up decision making. Another marked
trend is the shift toward more proactive treatment protocols
using anti-VEGF therapy to improve patient outcomes and
better manage the burden of care in terms of injections and
visits [13, 14].
In clinical trial settings, pro re nata (PRN) or treatment as
needed protocols require regular monitoring and strict
retreatment criteria when signs of active neovascularisation
are present, e.g., ﬂuid on OCT, new or persistent
haemorrhage, decreased visual acuity (VA) attributable to
disease activity as compared with the previous examination,
or dye leakage or increased lesion size on fundus
Table 1 Action on nAMD service provision: key points
• Recommendations for service providers
° Maintain high-quality service provision standards without
compromise for target time to treat, maintenance of review intervals
for timely proactive treatment and appropriate discharge.
° Ensure continuing proactive treatment strategies to maximise and
maintain vision beneﬁts.
° Monitor and benchmark treatment outcomes, attendance compliance
and discharge rates in the context of service slippage.
° Ensure dedicated ophthalmic IT and failsafe administration support.
• Practices to meet current and future demand
° Service providers are encouraged to establish a service model best
suited to local circumstances and patient population but which
allows patients with nAMD to receive timely and effective treatment
with optimal follow-up.
° An efﬁcient MDT with upskilled AHPs helps optimise available
consultant resource.
° Examples of good practice and service development include clinical
assessments and evaluation of images undertaken by trained AHPs
under the supervision of a retinal specialist with expertise in
managing nAMD, non-medical healthcare professional-led
intravitreal injection services and follow-up clinics in the community
for surveillance of treated nAMD patients with quiescent disease.
° Consultation based on SD-OCT images acquired either by
community optometrists or AHPs within the HES may help to triage
individuals with suspected macular disease and provide faster access
to treatment for urgent cases.
° Fast and secure IT links are necessary.
° For nAMD patients with quiescent disease following anti-VEGF
treatment, consider the feasibility of utilising community-based
optometrists to make decisions about the need for hospital
assessment and treatment, subject to ongoing training and
consultant-led governance.
• Group review of NICE guideline for diagnosis and management of
AMD
° NICE technology appraisal recommendations must normally be
implemented by the NHS within 90 days of the date of publication of
ﬁnal guidance, unless otherwise speciﬁed. By contrast, it is not
mandatory to apply the recommendations in NICE guideline NG82.
° NICE does not recommend the routine use of ICGA as part of the
diagnostic and therapeutic processes, but acknowledges that it is
considered particularly useful for identifying PCV, a subtype of
nAMD.
° There is an opportunity to seek commissioning support for
antiangiogenic treatment of nAMD patients with starting vision
better than 6/12 or if vision is worse than 6/96 in a second eye.
° There may be a role for adjunctive PDT in individual nAMD cases,
while laser may be a potential treatment option for extrafoveal CNV
lesions.
° Effective low-vision support services are necessary as part of routine
care and all medical retina units should have access to LVA services.
° Centres should seek funding for an ECLO service where absent.
AHPs allied healthcare professionals, anti-VEGF anti-vascular
endothelial growth factor, CNV choroidal neovascularisation, ECLO
Eye Clinic Liaison Ofﬁcer, LVA low-vision aid, HES hospital eye
service, MDT multidisciplinary team, ICGA indocyanine green
angiography, nAMD neovascular age-related macular degeneration,
NICE National Institute for Health and Care Excellence, PCV
polypoidal choroidal vasculopathy, PDT photodynamic therapy, SD-
OCT spectral domain optical coherence tomography
Table 2 Action on nAMD clinical management: key points
• Switching therapies and stopping treatment
° Treatment switch to a different anti-VEGF drug may be beneﬁcial in
a subset of nAMD patients who have no improvement in vision and
no improvement in ﬂuid or pigment epithelial detachment following
prior antiangiogenic treatment.
° Decisions to withhold or stop anti-VEGF treatment need to be
patient-centred and tailored to the needs of individual patients.
° Discharge from clinic may be considered if there are robust
community referral systems in place.
° A structured monitoring programme for speciﬁc cohorts of inactive
nAMD patients (e.g., better-seeing eyes) meeting local criteria for
discharge merits consideration.
• Monitoring non-affected fellow eyes
° There is a high burden of second eye involvement in patients
receiving treatment for unilateral nAMD and regular monitoring of
non-affected fellow eyes is necessary.
° Unilateral nAMD patients extended beyond 8-weekly retreatment
might beneﬁt from OCT monitoring at shorter intervals to prevent
worse outcomes in the second eye.
° Home monitoring and regular eye tests can help identify subtle
changes in visual function that may suggest increasing nAMD
activity.
° Fellow eye involvement may be considered when determining an
appropriate monitoring interval.
• Practicalities of intravitreal injection therapy
° The use of peri-injection antibiotics is no longer recommended;
however, practitioners should adhere to local protocol until changed.
° Topical administration of iopidine 1% (in cases known to have IOP
spikes post injection) 1 h prior to intravitreal anti-VEGF injection
can help reduce the magnitude of a rise in IOP post injection.
° For injection clinics led by AHPs, there should be an appropriately
trained clinician available to manage any urgent ophthalmological or
medical complication.
° Bilateral intravitreal injections during the same visit must be
performed as separate sequential procedures.
° Follow-up injection visits should be coordinated by a failsafe
administrator to ensure that all patients receive appointments and
retreatments at the appropriate time without undue deferral.
AHPs allied healthcare professionals, anti-VEGF anti-vascular
endothelial growth factor, IOP intraocular pressure, nAMD neovas-
cular age-related macular degeneration, OCT optical coherence
tomography
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ﬂuorescein angiography (FFA) [15]. However, actual
treatment patterns with PRN regimens in routine practice
can follow less stringent retreatment criteria and variable or
indeterminate monitoring. As such, a PRN retreatment
regimen often tends to lead to undertreatment with an
insufﬁcient frequency of anti-VEGF injections, resulting in
poorer vision outcomes than those observed in pivotal
nAMD randomised controlled trials [13, 16–19].
A treat-and-extend dosing regimen can help reduce treat-
ment burden by extending injection intervals when possible
and achieves visual outcomes superior to as-needed treatment
regimens [16, 20]. Furthermore, the 1-year results from a
large randomised clinical trial suggest that a treat-and-extend
regimen is a viable and effective alternative to ﬁxed monthly
therapy in treatment-naive nAMD patients [21].
Recommendations for service providers
Adequate capacity and funding of essential HES macular
treatment services remain paramount. Recommendations for
high-quality care in nAMD services include the following.
Maintain high-quality service provision standards without
compromise
Several exemplar models of care delivery have been
successfully implemented across many parts of the HES.
However, adequate investment remains an issue in
maintaining provision of high-quality macular clinic
services, particularly with regard to funding for recruit-
ment, equipment and space. Ophthalmology is the second
largest provider of outpatient care in the NHS, accounting
for 8.1% of all English NHS outpatient attendances in the
year to March 2017 (Table 3) [22]. The number of
attended outpatient appointments in English NHS hospi-
tals and English NHS-commissioned activity in the
independent sector has risen signiﬁcantly, from 51.9
million in 2006–2007 to 93.9 million in 2016–2017 [22].
It is recommended that there should be no compromise in
service provision standards. Key performance indicators
and metrics need to be established and agreed locally.
Local pathways should detail nAMD target time to treat
and maintenance of review intervals to ensure proactive
treatment regimens are delivered on time and appropriate
discharge for patients deemed low risk or no longer bene-
ﬁting from treatment. Treatment delay following diagnosis
or during ongoing management of active disease may result
in clinically signiﬁcant visual loss [23, 24]. Signiﬁcant
delay throughout the early stages of the nAMD care path-
way has been reported [25]. Delays in intended care indicate
a lack of capacity within the HES, or more speciﬁcally a
signiﬁcant mismatch between ophthalmic capacity and
demand [26, 27].
Moorﬁelds Eye Hospital is the largest specialist eye
hospital in the UK, which saw 509,052 outpatients in 2014–
2015 compared with 396,058 in 2010–2011 [27]. During the
same period, outpatient activity in the medical retina sub-
specialty increased by 36% from 79,226 to 107,888. Davis
et al. [27] reported that medical retina, despite being known
to have a large follow-up workload, had a smaller percen-
tage of lost to follow-up episodes than the more surgically
based subspecialties, suggesting that with appropriate dili-
gence it is possible to manage lost to follow-up events to
reduce risk to patients and avoid deterioration of sight. A
retrospective study of a consecutive series of patients (n=
195) treated with intravitreal injection therapy for nAMD in
southeast Scotland between 2013 and 2015 found that the
mean time from initial ophthalmic assessment to ﬁrst intra-
vitreal injection treatment was 31.5 days, considerably
longer than the recommended service target of 2 weeks [25].
Moorﬁelds Eye Hospital has developed a telephone text
reminder system for all patients 2 days before their sched-
uled appointment, an approach that may be appropriate
especially for elderly people or their relatives [27].
Ensure continuing proactive treatment strategies to
maximise and maintain vision beneﬁts
The treatment goal is to achieve the best possible VA
beneﬁts through early initiation of therapy and maintain-
ing continuous timely retreatment. A proactive treatment
Table 3 NHS-funded outpatient activity in England 2016-17: top ﬁve
treatment specialties with the greatest number of attendances [22]
Treatment specialty Attendances Non-
attendances
(DNAs)
Ratio of non-
attendances to
attendances
Trauma and
orthopaedics
7,779,904 607,881 0.08
Ophthalmology 7,642,363 651,106 0.09
Physiotherapy 5,058,780 490,276 0.10
Diagnostic imaging 4,048,842 49,277 0.01
Obstetrics 3,722,720 277,859 0.07
Top ﬁve treatment
specialties
28,252,609 2,076,399 0.07
All treatment
specialties
93,944,301 7,938,009 0.08
See ref. [22]. © Copyright © 2017, NHS Digital (Health and Social
Care Information Centre)
Information from NHS Digital, licenced under the current version of
the Open Government Licence. https://digital.nhs.uk/catalogue/
PUB30154
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approach with a one-stop service where assessment and
treatment occur at the same appointment minimises the
need for intervening visits, supported by clear pathways
that deﬁne criteria for disease stability and treatment dis-
continuation. Furthermore, a one-stop service model
reduces the likelihood of disease resurgence that can occur
between separate monitoring and treatment appointments.
A manageable travel burden for patients and carers may
also reduce the potential for missed appointments.
The ideal treatment regimen for anti-VEGF manage-
ment in nAMD, identiﬁed by an international working
group of retina specialists, should seek to maximise and
maintain VA beneﬁts for all patients, titrate treatment
intervals to match patients' needs and treat at each mon-
itoring visit [14].
Treatment extension, when applied according to the
licensed treatment posology, allows for injection intervals to
be gradually increased in a stepwise manner to maintain
stable visual and/or anatomic outcomes. Extension may be
considered for eyes without macular ﬂuid on OCT and
stable vision [28] or stable chronic ﬂuid at optimal treatment
intervals. The criteria for maintaining or shortening treat-
ment intervals are persistent macular ﬂuid with stable
vision, recurrent ﬂuid, decrease in vision in the presence of
ﬂuid, new macular haemorrhage, new choroidal neovascu-
larisation (CNV) or any other sign(s) of exudative disease
activity considered vision threatening in the opinion of the
treating clinician [28].
Monitor and benchmark treatment outcomes, attendance
compliance and discharge rates
Signiﬁcant variations in injection frequency, follow-up
monitoring and reported outcomes have been observed
between clinic centres providing the same therapeutic
regimen for nAMD [29, 30]. A study by the UK AMD
EMR Users Group of 13 UK centres using a set protocol for
managing treatment-naive nAMD found that the mean inter-
centre VA change from baseline to month 12 varied from
+6.9 to −0.6 Early Treatment of Diabetic Retinopathy
Study (ETDRS) letters (mean improvement of 2.5 letters)
[30]. Differences between centres persisted after adjustment
for baseline age, starting vision and treatment and visit
frequency. There is also signiﬁcant variation between cen-
tres in the proportion of treated eyes with a VA ≥70 letters
at month 12 follow-up.
Clinical audit of outcomes helps benchmark standards of
care and impact healthcare quality improvements. The use
of multiple outcome measures to evaluate the quality of
service provision for nAMD is recommended, covering
both VA and process review. Talks et al. [29] recommended
the following as a minimum requirement for ongoing ser-
vice evaluation of treated eyes:
● Proportion of patients with VA <35 and ≥70 letters at
baseline and at 1-year follow-up;
● Number of treatments administered in 1 year;
● Rate of retention of patients at 1 year; and
● Discharge policies and futility criteria [29].
A minimum set of outcome measures for tracking,
benchmarking and improving care for nAMD has been pro-
posed by another working group of international experts [31].
They recommend standardised measurement of: visual func-
tioning and quality of life (distance VA, mobility and inde-
pendence, emotional well-being, reading speed and accessing
information); number of treatments; complications of treat-
ment; and disease control. VA outcomes of treated eyes
should capture data for mean change in VA from baseline and
the proportion of eyes gaining, losing and maintaining vision
(losing <5 letters). While highly useful as measures of care,
the practicalities of delivering these outcome measures in
busy NHS clinical practices is open to question.
Service providers nonetheless are encouraged to
add or consider additional outcomes to meet their
speciﬁc requirements. A ceiling effect limits potential for
improvement in eyes with good vision at baseline [32].
Actual VA outcomes achieved and maintenance of the level
of vision when disease stability is achieved are good mea-
sures for judging the quality of care for patients with nAMD
treated with anti-VEGF therapy [32]. Each centre should
actively monitor and audit service slippage.
Service metrics such as time to ﬁrst treatment and
compliance with intended review intervals may also be used
as key performance indicators when benchmarking service
standards in a unit.
Ensure dedicated ophthalmic IT and failsafe administration
support
Electronic Medical Record (EMR) systems are recom-
mended as an integral service component, covering
documentation of the management plan and review
of results, allowing service providers to monitor the number
of new patients assessed each week and annual discharge
numbers as well as to track and audit treatment outcomes.
Medical retina centres require dedicated ophthalmic infor-
mation technology (IT) support and failsafe administration
systems, preferably with specialised administration per-
sonnel, for example, an injection service coordinator. EMR
suppliers are encouraged to provide seamless software
support.
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Practices for managing capacity issues to
meet current and future demand
The UK has fewer consultant ophthalmologists per capita
than other major European countries [33]. Driven by an
ageing and a growing population, case numbers of nAMD in
the UK are predicted to increase by 29% between 2015 and
2025 and by 59% from 2015 to 2035 [34]. Ophthalmologists
have introduced a number of successful newer organisa-
tional models of ophthalmic care and service redesign to
meet current and future case demand (Table 4) [34].
Anti-VEGF injection clinics led by nurses and other
AHPs
Use of non-medical staff for injection administration
remains off-label for the licensed intravitreal anti-VEGF
drugs. Notwithstanding this, to address signiﬁcant workload
on ophthalmology clinics, allied healthcare professional
(AHP)-led intravitreal injection clinics have been established
by multiple HES centres. Ophthalmic nurse practitioners,
hospital optometrists, technicians and orthoptists play an
increasingly signiﬁcant role in the delivery of routine retina
care, with extended roles helping to expand service provi-
sion capacity [35–37]. Results show positive patient satis-
faction with a nurse-led injection service, with little variation
in patient experience when compared to a doctor-led service,
and an acceptable safety proﬁle [35, 38].
Prioritising and simplifying direct referrals for faster
access to macular treatment
Manchester Royal Eye Hospital has utilised the training of its
specialist optometrists and OCT imaging to establish an
Emergency Macular Clinic (EMAC), an initiative providing
streamlined in-house triage for accurate early diagnosis and
prompt access to treatment for individuals with macular dis-
orders. The EMAC offers a rapid access, virtual triage service
for people referred directly by high-street optometrists with
suspected or conﬁrmed macular problems, without the need
for prior OCT assessment or detailed referral forms. It ensures
prioritisation and direct referral to the macular treatment
centre for urgent treatment of patients with nAMD, central
retinal vein occlusion, branch retinal vein occlusion (BRVO)
with macular oedema and myopic CNV. Patients with less
urgent conditions such as milder cases of BRVO, diabetic
macular oedema (DMO) or macular hole are triaged for
outpatient review by a medical or surgical retina consultant.
The Emergency Macular Clinic service pathway is detailed
more fully in Fig. 3. The EMAC functions as a walk-in ser-
vice, providing same-day assessment if the patient can attend
and, as a minimum standard, aims for appointment within 48
h from ﬁrst contact. A nurse checks VA and an ophthalmic
science practitioner carries out an OCT scan. Specialist
trained optometrists review OCT scans within 24 h of ima-
ging and decide on the most appropriate onward referral
route. This helps to quickly identify cases that require urgent
intravitreal treatment to prevent further sight loss. Approxi-
mately 80 new referrals are assessed and triaged each month.
The main beneﬁt is accurate macular assessment using OCT,
allowing faster access to treatment for those with conﬁrmed
sight-threatening macular conditions. Key performance indi-
cators are time to ﬁrst review in EMAC (within 2 days) and
time to ﬁrst treatment (as soon as possible after review in
EMAC with a maximum duration of 14 days from the initial
referral to EMAC). Manchester Royal Eye Hospital also
records and reports other key performance indicators monthly,
including compliance with review intervals (within 7 days of
intended), complications and patient experience (maximum
patient journey including assessment and treatment of 1 h
from arrival to departure at the satellite units).
The HES in Shefﬁeld has also been running weekly fast-
track clinics for new suspected nAMD referrals, led by
highly trained and experienced nurse practitioners. This
allows for: discharge at the outset for false positives or
further referral to other specialties; referral to Low Vision
Aid (LVA) services and the Eye Clinic Liaison Ofﬁcer
(ECLO) for those whose vision falls outside the treatment
criteria or for advice and support about potential fellow eye
involvement; and counselling, prompt FFA/imaging and
information sharing about disease management and treat-
ment for those who are diagnosed with nAMD.
Table 4 Practical steps or actions for service improvement in the
management of nAMD
Options and practical steps for service improvements in the
management of nAMD include, but are not limited to:
▪ Direct electronic referral for suspected nAMD can facilitate rapid
access to clinical assessment and imaging and needs to be managed
as direct appointment bookings to ensure allocation to the correct
clinic.
▪ Trained non-medical AHPs may help triage new patient referrals to
fast-track prompt treatment or discharge decision making.
▪ Virtual (without actual consultation) clinic models may be
provided in the HES or at peripheral sites, with decisions about
treatment made by the consultant at a virtual reporting session or by
non-medical AHPs directly. Training, audit and governance must be
appropriate.
▪ Decentralised image acquisition for nAMD virtual clinics where
community OCT and cameras are already available and IT data
transfer systems are available.
▪ Eye departments have successfully implemented AHP-led anti-
VEGF injection clinics.
▪ Risk stratiﬁcation of patients who are no longer receiving active
treatment may allow graded discharge options.
AHPs allied healthcare professionals, anti-VEGF anti-vascular
endothelial growth factor, HES hospital eye service, nAMD neovas-
cular age-related macular degeneration, OCT optical coherence
tomography
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Virtual (without actual consultation) clinic
assessments
Remote evaluation of patients may not only enable earlier
detection but also provide for effective monitoring of
vision-threatening diseases such as nAMD, diabetic reti-
nopathy and glaucoma [39, 40]. Consultation based on SD-
OCT images acquired by community optometrists may help
to triage individuals with suspected macular disease and
provide faster access to treatment for urgent cases [40].
Assessments may be undertaken by trained optometrists,
nurse practitioners or orthoptists who work as part of a team
or network under the supervision of a medical retina spe-
cialist in the community or hospital. Optometrist-led stable
AMD clinics in the hospital setting may also reduce the
burden on existing macular treatment services and have
been shown to be safe and efﬁcient [41]. Community
follow-up by trained optometrists of previously treated and
stable nAMD patients (usually patients who have not
required any treatment for at least 6 months of hospital
follow-up) may also augment hospital macular services,
with medical retina consultant-led governance.
Following the introduction of virtual follow-up
appointments for monitoring eligible nAMD patients at
Leicester Royal Inﬁrmary Retina department, the proportion
of patients (n= 196) with signiﬁcant improvement in mean
VA (≥15 letters) increased markedly, despite an unchanged
PRN treatment regimen (23.1% with an average of 5.9
injections per patient per year for 2012–2013 compared
with 6.9% and an average yearly frequency of 5.6 injections
for 2010 and 2011) [42]. The mean time between appoint-
ments (follow-up or treatment) decreased from a mean
6.9 weeks to a mean of 5.3 weeks. Mean patient waiting
time was 71.4 ± 24.1 min for a conventional hospital visit
and 47.3 ± 18.6 min for a virtual clinic appointment.
Evidence shows that virtual medical retina clinics can be
implemented successfully using existing resources within a
HES [43]. Open to non-urgent external referrals and to
existing patients in an outpatient clinic, all patients received
VA testing, dilated fundus photography and OCT scans,
with grading performed by consultants, fellows and AHPs
later on. Review of ﬁrst attendances between September
2016 and May 2017 (n= 1729 patients) showed that the
main reasons for referral to face-to-face consultation
were image quality (34.7%) and detection of potentially
treatable disease (20.2%). Of those referred externally,
45.5% were discharged, 37.1% continued in the virtual
clinic and 17.4% were brought in for a face-to-face con-
sultation. As observed by Kortuem et al. [43], virtual
medical retina clinics offer a promising solution to ensure
patients are seen and treated promptly, and may serve as
ﬁrst-line rapid access clinics.
Risk stratiﬁcation and effective triage are necessary, as is
identiﬁcation of stable patients who may be suitable for
monitoring without treatment. A number of centres have
implemented stable nAMD clinics (e.g., no treatment given
in the previous ~6 to 12 months, depending on local pro-
tocol in place) involving nurse-led reading centres for
grading of previously acquired OCT scans (Fig. 4).
It is acknowledged that slit lamp examination may reveal
additional ﬁndings when compared with virtual clinic
assessment using combined SD-OCT assessment and colour
fundus photography. A service evaluation at Hull and East
Yorkshire NHS Trust found that, in a cohort of 242 patients,
only 2.5% had isolated retinal haemorrhage undetected with
colour imaging and where there were no other OCT features
indicating disease activity, arguably an acceptable risk given
the beneﬁts of higher throughput with virtual clinics [44].
Electronic referrals by community optometrists
Timely referral of suspected nAMD can potentially mini-
mise vision loss and maximise possible treatment beneﬁt by
providing rapid access to assessment and treatment. The
NICE guideline committee commented that there was no
evidence to suggest that particular referral pathways are
more effective than others, other than the clear beneﬁt of
SUSPECT MACULAR DISEASE
1. Optometrist referral or 
2. Paent from Emergency Eye Centre
REVIEW  OF IMAGES AND NOTES BY 
OPTOMETRIST
EMAC APPOINTMENT
VA + dilaon (nurse/CSW)
PATIENT REQUIRING 
URGENT INTRAVITREAL 
THERAPY (<2/52 from 
referral) e.g., 
nAMD
Myopic CNV
CRVO
BRVO with macular oedema
PATIENT REQUIRING SOON 
REVIEW (4-6 weeks )
e.g., 
BRVO centre involving
DMO
CSR
PATIENT REQUIRING 
ROUTINE REVIEW (6 
weeks+) e.g., 
RVO - not centre involving
nAMD - untreatable 
Dry AMD
VMT, Macular Hole, ERM
URGENT MACULAR 
TREATMENT CENTRE 
APPOINTMENT TO 
COMMENCE INJECTION
THERAPY
MEDICAL OR SURGICAL 
RETINA CLINIC AS 
APPROPRIATE
MEDICAL RETINA CLINIC
Aim within 48 hours
Aim within 24 hours
Fig. 3 Flow diagram showing Emergency Macular Clinic (EMAC)
service pathway, Manchester Royal Eye Hospital. AMD age-related
macular degeneration, BRVO branch retinal vein occlusion, CNV
choroidal neovascularisation, CRVO central retinal vein occlusion,
CSR central serous retinopathy, CSW care support worker, DMO
diabetic macular oedema, ERM epiretinal membrane, OCT optical
coherence tomography, RVO retinal vein occlusion, VMT vitreoma-
cular traction. Information within ﬂowchart courtesy of Mr Sajjad
Mahmood, Manchester Royal Eye Hospital, Manchester, UK
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direct referral. However, local areas should have clear
pathways in place for referral, discharge and re-referral. In
Scotland, an e-referral infrastructure has been established.
Electronic referral direct from community optometrists to
the HES may help avoid unnecessary outpatient appoint-
ments, reduce waiting times and allow patients to be
promptly vetted into the correct specialist clinic [45].
Follow-up and monitoring of quiescent nAMD by
community optometrists
Locally commissioned enhanced optometric services pro-
vided by accredited community optometrists have proven to
be effective for cataract, glaucoma and primary eye care,
with patient management commensurate with usual care
standards [46]. Collaborative shared care of nAMD offers
the potential to reduce workload in hospitals and increase
overall capacity to manage the nAMD population more
effectively and to manage non-neovascular AMD patients
[47]. Devolving responsibilities for monitoring nAMD
patients with inactive or quiescent lesions to community
optometrists may be a viable option to help release addi-
tional capacity within the HES, but this requires ongoing
training and quality assurance governance.
Monitoring of quiescent nAMD for reactivation may
avoid or prevent irrecoverable sight loss from deterioration
of the lesion. Perspectives of shared care for monitoring
nAMD indicate that there are concerns about the potential
for delays with referrals to secondary care if stable nAMD
became active again [48]. Continuous and systematic spe-
cialist training for optometrists, under the supervision of
ophthalmologists, is required to ensure that optometrists can
accurately and conﬁdently elicit the signs of macular dis-
ease and thereby minimise unnecessary referrals due to
image quality or difﬁculty with scan interpretation [48].
The Effectiveness of Community versus Hospital Eye
Service follow-up for patients with neovascular age-related
macular degeneration with quiescent disease (ECHoES) trial
concluded that the ability of optometrists, with appropriate
training, to make nAMD retreatment decisions from vign-
ettes is not inferior to that of ophthalmologists [47]. Various
barriers to implementing shared care pathways for mon-
itoring quiescent nAMD were identiﬁed, such as concerns
about high-street optometrist competency and potential
delays with referrals to secondary care if stable nAMD
became active again [48]. The duration of monitoring is not
agreed upon but the probability of recurrence declines the
longer the treatment-free interval [49].
Recommendations for maintaining effective local
treatment provision
Bespoke approaches to service delivery allow providers to
retain ﬂexibility for location and patient population to
ensure an efﬁcient nAMD service is made available to
patients.
In busy clinical practice, medical retina service models
that combine the management of nAMD with other retinal
vascular diseases appear to function well. For example,
combined intravitreal injection clinics for treating multiple
retinal disease entities helps to maintain staff enthusiasm
and foster good oversight of indication-speciﬁc protocols.
Different models of care utilising trained AHPs within the
HES can be effective in reducing time from initial pre-
sentation to referral, diagnosis and treatment. Separate vir-
tual clinics and assessment is a sound approach to the
management of stable nAMD patients and also for those on
active treatment.
Fast-track referral models for prompt macular assessment
demonstrate that a ‘virtual’ review model relying on inter-
pretation of images by non-medically trained graders is
feasible and safe. Further treatment provision is likely to
entail intermittent face-to-face clinician consultations in
combination with regular clinic assessments and follow-up
No  required 
for last 6 months 
Refer to stable nAMD 
clinic 
LogMAR VA, IOP, 
on and OCT 
assessment  
OCT image reading by 
nurse (2 days later)
Clinical Decision 
Stable: 3/12 monitor 
Ac ve: retreat 
Fig. 4 Pathway for nurse-led stable nAMD service reviewing ~40
patients per clinic session, Moorﬁelds Eye Hospital, London, UK. IOP
intraocular pressure, logMAR logarithm of the minimum angle of
resolution, nAMD neovascular age-related macular degeneration, OCT
optical coherence tomography, VA visual acuity. Information within
ﬂowchart courtesy of Mr Praveen Patel, Moorﬁelds Eye Hospital,
London, UK
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review of OCT scans and case records. Slit lamp assessment
may not be required at every clinic visit for follow-up
patients.
Community care models beyond the hospital setting can
be effectively established to increase patient throughput
capacity but require support and investment in training for
primary care eye professionals. Service users need the
support of a good transport network. Moreover, adequate
space is required and some centres have decommissioned
mobile clinic services. A good IT infrastructure is also
necessary for this to be effective.
The concept of so-called virtual clinics has been used to
develop newer approaches to the management of stable
nAMD patients. Colour fundus photographs and OCT
images are obtained from patients, with separate remote
decision making subsequently by clinicians or AHPs. Vir-
tual reporting sessions allow ophthalmologists and AHPs
additional ﬂexibility and time to consult colleagues for
challenging or complex cases.
When developing proposed OCT assessment models
for nAMD that do not involve face-to-face consultation
with ophthalmologists, practitioners should ideally discuss
service redesign initiatives with patient representatives and
consult service users for non-HES sites.
Colour photography complements virtual OCT imaging
sessions. With the growing practice of image assessment
and grading by non-ophthalmologists as part of consultant-
led multidisciplinary team (MDT) approaches, a service
lead should be appointed to oversee continued training,
audit and quality assurance strategies to ensure that all staff
and team members stay up to date.
Considerations for future service provision include pre-
dictive modelling of estimated patient population numbers
and expected timings of a likely plateau in workload
volume. Embracing newer technology, such as automated
OCT analysis or grading and triage by artiﬁcial intelligence,
may further improve referral quality and allow reliable
comprehensive monitoring strategies for long-term patient
management.
Group review of NICE guideline for diagnosis
and management of AMD
The latest guideline from NICE aims to improve the speed
at which people are diagnosed and treated to prevent sight
loss [12]. Table 5 summarises the key NICE recommen-
dations for nAMD and Table 6 outlines the NICE nAMD
classiﬁcation. The terms late AMD (wet active) and late
AMD (wet inactive) used in the NICE guideline are referred
to in this article as active and inactive nAMD, respectively.
The advice from NICE is designed to help optimise service
organisation and identiﬁcation of risk factors, and improve
Table 5 Brief overview of NICE advice for management of
neovascular age-related macular degeneration [12]
Referral and diagnosis:
▪ People with suspected active nAMD must be urgently referred to a
macula service, normally within 1 working day.
▪ People with suspected active nAMD should be offered OCT and
FFA to conﬁrm the diagnosis if OCT alone does not exclude
neovascular disease.
Pharmacological management with antiangiogenic therapy:
▪ Treatment should be offered within 14 days of referral to the macula
service for eyes with a conﬁrmed diagnosis of active nAMD for
which antiangiogenic therapy is recommended.
▪ In eyes with VA of 6/96 or worse (≤25 letters), anti-VEGF treatment
for nAMD may be considered only if a visual function beneﬁt
is expected (e.g., if the affected eye is the person's better-seeing
eye).
▪ Practitioners are reminded that anti-VEGF treatment for eyes with
nAMD and VA better than 6/12 (≥70 letters) is clinically effective
and may be cost effective depending on the regimen used, although
not currently recommended.
▪ Practitioners are advised not to offer PDT alone for active nAMD.
NICE recommends that PDT is only offered as an adjunct to anti-
VEGF therapy as second-line treatment for active nAMD in the
context of a randomised controlled trial.
▪ Intravitreal corticosteroids should not be offered as an adjunct to
anti-VEGF therapy for active nAMD.
Switching and stopping antiangiogenic therapy:
▪ Practitioners may consider switching anti-VEGF treatment for
people with active nAMD if there are practical reasons for doing
so (e.g., if a different medicine can be given in a regimen the
person prefers) although the clinical beneﬁts are likely to be
limited.
▪ Observation without giving anti-VEGF treatment is recommended if
the disease appears stable.
▪ Stopping anti-VEGF treatment should be considered if the eye
develops severe, progressive loss of VA despite treatment and
treatment discontinued if the nAMD is inactive or there is no
prospect of functional improvement.
Non-pharmacological management of AMD: psychological therapies
and support strategies:
▪ People with AMD and visual impairment are at an increased risk of
depression and many may have other signiﬁcant comorbidities.
▪ Practitioners are advised to identify and manage depression
according to the NICE guideline on depression in adults with a
chronic physical health problem.a
▪ Guidance on optimising care for adults with multiple long-term
conditions is available in the NICE guideline on multimorbidity.b
▪ Certiﬁcation of visual impairment should be offered to all people
with AMD as soon as they become eligible, even if they are
still receiving active treatment, with referral to low-vision
services considered for those with AMD causing visual
impairment.
Monitoring of active nAMD, inactive nAMD and those with AMD
discharged from hospital services:
▪ Active nAMD: offer ongoing monitoring with OCT for both eyes.
▪ Inactive nAMD: review both eyes at monitoring appointments.
▪ Discharged:
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diagnosis, management and review of AMD. However, it is
not mandatory to apply the guideline recommendations and
the guideline does not override the responsibility of clin-
icians to make decisions appropriate to the circumstances of
each patient [12].
In contrast, recommended treatment options outlined in
NICE technology appraisal guidance must normally be
made available by the NHS within 90 days of the date of
publication of ﬁnal guidance, unless otherwise speciﬁed in
the guidance. If there is a signiﬁcant budget impact, the
introduction may be phased over a longer period than the
standard 90 days. When exercising their judgement, health
professionals are expected to take NICE guidance fully into
account, alongside the individual needs, preferences and
values of their patients. If NICE guidance is considered not
applicable to the services provided or commissioned, that
decision should be recorded and reviewed should services
change or the organisation takes on new services [50].
The need for further diagnostic investigations beyond
OCT and clinical assessment, for example, with FFA or
indocyanine green angiography (ICGA), will depend on
judgement as to whether these will likely alter or delay the
management plan. NICE does not recommend the routine
use of ICGA as part of the diagnostic and therapeutic pro-
cesses, but acknowledges that it is considered particularly
useful for identifying polypoidal choroidal vasculopathy
(PCV), a subtype of nAMD found in approximately 10% of
Caucasian nAMD patients [51].
The 2-week target for time from presentation to treatment
(total period from referral to diagnosis and diagnosis to
treatment) is speciﬁed by NICE in the recognition that a
shorter delay would maximise the chances of preserving
vision, as vision loss from active nAMD can be acute and
rapid [12]. This target is consistent with professional gui-
dance from the Royal College of Ophthalmologists [52]
and, according to stakeholder feedback from providers and
commissioners, should be achievable in all centres. Some
centres aim to provide treatment for eligible nAMD cases
within 48 h of referral.
Ranibizumab (Lucentis®, Novartis Europharm Limited,
Dublin, Ireland) and aﬂibercept (Eylea®, Bayer AG, Lever-
kusen, Germany) are licensed intravitreal anti-VEGF drugs
(antiangiogenic agents) indicated for adults for the treatment
of nAMD as well as for visual impairment due to other
retinal conditions [53, 54]. NICE guidance recommends
both agents as ﬁrst-line treatment options for adults with
nAMD who meet the following baseline clinical criteria:
best corrected VA is between 6/12 and 6/96, there is no
permanent structural damage to the central fovea, the lesion
size is less than or equal to 12 disc areas in size and there is
evidence of recent presumed disease progression (blood
vessel growth, as indicated by FFA, or recent VA changes)
[55, 56]. Furthermore, the manufacturer must also provide
the drug with the discount agreed in the patient access
scheme. Ranibizumab and aﬂibercept are also accepted for
use in adults with nAMD in NHS Scotland [57], NHS Wales
and Health and Social Care Board Northern Ireland.
There is an opportunity to seek commissioning support for
antiangiogenic treatment of nAMD patients with starting
vision better than 6/12 on the basis of current evidence. The
guideline from NICE acknowledges that treatment of nAMD
patients with initial VA >6/12 may be beneﬁcial and that
treatment may be of beneﬁt for those whose vision is 6/96 or
worse. Evidence from the UK EMR Users Group supports the
immediate treatment of nAMD in patients with initial good
baseline vision better than 6/12, representing a cost-effective
strategy compared with current guidance of initiating treat-
ment only at a presenting vision of 6/12 or worse [58, 59].
Previous guidance on the use of photodynamic therapy
(PDT) for AMD has been updated and replaced by NICE
guideline NG82. Practitioners are advised not to offer PDT
as an adjunct to intravitreal anti-VEGF therapy as ﬁrst-line
treatment for active nAMD. The authors believe there
remains a role in some circumstances for adjunctive PDT in
nAMD. Combining PDT with anti-VEGF treatment may
provide additional functional beneﬁt over anti-VEGF
Table 5 (continued)
° Patients should be advised to self-monitor their AMD, consult their
primary eye care professional if their vision changes or new
symptoms emerge (e.g., blurred or grey patch in their vision, straight
lines appearing distorted or objects appearing smaller than normal)
and continue to attend routine sight-tests with their community
optometrist; and
° A clear local pathway should be agreed covering ongoing
management and re-referral when necessary following discharge to
primary care.
Information and support:
▪ Information in accessible formats should be provided for people with
nAMD, allowing sufﬁcient time to discuss the concerns and
questions that the persons have about their diagnosis, treatment and
prospects for their vision. Peer support is encouraged.
▪ Patients should be counselled about the possibility of developing
visual hallucinations associated with retinal dysfunction (Charles
Bonnet syndrome), a condition that typically improves but can last
several years.
Anti-VEGF anti-vascular endothelial growth factor, FFA fundus
ﬂuorescein angiography, nAMD neovascular age-related macular
degeneration, OCT optical coherence tomography, PDT photodynamic
therapy, VA visual acuity
aAvailable at: https://www.nice.org.uk/guidance/cg91
bAvailable at: https://www.nice.org.uk/guidance/ng56
See ref. [12]. NICE © 2018. All rights reserved. Subject to Notice of
rights (https://www.nice.org.uk/terms-and-conditions#notice-of-rights)
NICE guidance is prepared for the National Health Service in England.
All NICE guidance is subject to regular review and may be updated or
withdrawn. NICE accepts no responsibility for the use of its content in
this product/publication.
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monotherapy and decrease the burden of intravitreal injec-
tions in certain cases of idiopathic PCV [60]. The Action on
nAMD group therefore encourages providers to maintain
effective dialogue with local commissioners to support
clinician judgement for the use of adjunctive PDT for
nAMD on an exceptional individual case-by-case basis if
there is expected to be a likely beneﬁt. Some practitioners
also believe that laser may be a potential treatment option
for extrafoveal CNV lesions.
Non-affected contralateral eyes should be scanned
whenever the eye undergoing treatment for nAMD is being
scanned. Only a limited number of OCT scans may be
necessary in the ﬁrst year of treatment, but careful mon-
itoring for potential fellow eye involvement is advised, for
example, by ensuring measures are in place to detect
early signs of decreased vision [61]. That said, however,
routine OCT imaging of treated eyes may give
more information regarding treatment response which could
help in determining approach to treatment in year 2 and
beyond.
Table 7 shows several known risk factors for AMD [12].
Current smokers should be offered smoking cessation
advice and support. Initiation of AREDS vitamin supple-
ments in patients with unilateral nAMD is considered to
be cost saving and more effective than no supplement
use, according to a study of combined trial and real-
world outcomes data by the UK EMR AMD Research
Group [62].
The NICE guideline underscores the importance of
information provision as part of a well-organised patient
pathway. Low-vision support services assist in the provision
of information for those with visual loss, provide practical
advice in acute situations and signpost or facilitate access to
support services, including social care. The role of the Eye
Clinic Liaison Ofﬁcer is important in this regard, although
funding and space in clinics are sometimes barriers to
effective provision. Where absent, centres are encouraged to
secure funding for an ECLO service to enhance support for
people either newly diagnosed with sight loss or patients
with an ongoing eye condition. Community LVA provision
offers additional potential to ensure people receive the care
and support they need, with links to social care.
Furthermore, clinicians need to be mindful of the pre-
valence of undiagnosed depression and anxiety in nAMD
patients and ‘be alert to the opportunity to manage this’
[63]. An observational cross-sectional study by Senra et al.
[63] found that 12% of treated nAMD patients showed
clinical levels of depression and 17% had clinical levels of
anxiety. Depression was more frequent in patients during
the early stages of receiving anti-VEGF treatment.
Table 6 Classiﬁcation of active
and inactive nAMD, NICE 2018
guideline for diagnosis and
management of AMD [12]
nAMD classiﬁcation Deﬁnition
Late AMD (wet active) ▪ Classic CNV
▪ Occult (ﬁbrovascular PED and serous PED with neovascularisation)
▪ Mixed (predominantly or minimally classic CNV with occult CNV)
▪ RAP
▪ PCV
Late AMD (wet inactive) ▪ Fibrous scar
▪ Sub-foveal atrophy or ﬁbrosis secondary to a RPE tear
▪ Atrophy (absence or thinning of RPE and/or retina)
▪ Cystic degeneration (persistent intraretinal ﬂuid or tubulations unresponsive
to treatment)
NB Eyes classiﬁed as wet inactive may still develop or have a recurrence of
wet active AMD
See ref. [12]. NICE © 2018. All rights reserved. Subject to Notice of rights
AMD age-related macular degeneration, CNV choroidal neovascularisation, NICE National Institute for
Health and Care Excellence, PCV polypoidal choroidal vasculopathy, PED pigment epithelial detachment,
RAP retinal angiomatous proliferation, RPE retinal pigment epithelium
Table 7 Risk factors for AMD [12]
▪ Older age
▪ Presence of AMD in the other eye
▪ Family history of AMD
▪ Smoking
▪ Hypertension
▪ BMI ≥ 30 kg/m2
▪ Diet low in omega 3 and 6, vitamins, carotenoid and minerals
▪ Diet high in fat
▪ Lack of exercise
See ref. [12]. NICE © 2018. All rights reserved. Subject to Notice of
rights
AMD age-related macular degeneration, BMI body mass index
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Switching therapies and stopping treatment
Continued long-term treatment of active nAMD aims to
maintain or extend the macular structural and functional
gains while attempting to reduce or minimise the treatment
burden of clinic visits and injections [28]. Moreover, the
success of anti-VEGF treatment depends not just on the
treatment of active disease but also on the prevention of
disease recurrence and/or worsening [14].
Deﬁning response to treatment
The need to develop broader consensus on criteria for dis-
ease stability, treatment failure and stopping treatment has
been recognised previously [64]. Both functional and
morphologic responses to anti-VEGF treatment need to be
assessed when determining nonresponse or treatment fail-
ure. Amoaku et al. [64] suggested that the primary response
is best determined at month 4 following treatment initiation
with a loading phase of 3 consecutive monthly doses.
Secondary response on anti-VEGF maintenance therapy is
assessed from month 4 to month 11, with late response
determined at month 12 or after. Under the proposed
algorithm developed by Amoaku et al. [64], treatment with
anti-VEGF therapy should be continued in the absence of
morphological or functional deterioration. Poor or non-
response to anti-VEGF therapy warrants re-evaluation of
diagnosis and, if necessary, a switch to a different anti-
VEGF agent.
Switching between anti-VEGF agents for recalcitrant
or refractory nAMD
There may be a subset of nAMD patients for whom a switch
to a different anti-VEGF agent might be suitable [65], for
example, in cases of chronic treatment-resistant exudative
disease [66, 67]. Typical clinical reasons for switching agents
include persistent or recurrent subretinal and/or intraretinal
ﬂuid on SD-OCT and a trend toward decreased vision at 3 to
6 months after starting treatment. Morphological failure
characterised by the presence of persistent or recurrent ﬂuid
may not necessarily be associated with VA loss.
Outcomes data, largely from uncontrolled retrospective
studies, generally indicate signiﬁcantly improved anatomi-
cal outcomes and stabilisation of visual function after
treatment switch to another anti-VEGF drug for nAMD
patients unresponsive to previous anti-VEGF therapy.
However, any short-term functional improvement tends to
be limited and transient.
Most of the studies evaluating the potential beneﬁt of
changing antiangiogenic therapy in eyes considered insuf-
ﬁciently responsive to previous anti-VEGF treatment report
a statistically signiﬁcant reduction in retinal thickness on
OCT, with or without a change in visual function [65]. A
database observational study by Barthelmes et al. [68]
found no change in mean VA at 12 months of follow-up in
eyes that switched from ranibizumab to aﬂibercept but
observed a decrease in the proportion of nAMD lesions that
were graded as active. A national EMR database study in
the UK assessed visual beneﬁts for nAMD patients who had
undergone six continuous monthly ranibizumab injections
and were then switched to continuous aﬂibercept dosing,
matched to those on continuous ranibizumab therapy [69].
Following treatment switch, there was a transient signiﬁcant
improvement in VA that peaked at 0.9 ETDRS letters
3 months after the switch, whereas control patients who
continued on ranibizumab showed a steady decline in VA.
A meta-analysis of retrospective and prospective switch
studies evaluating visual and anatomical outcomes in
treatment-resistant nAMD patients switched to aﬂibercept
found a signiﬁcant improvement in central retinal thickness
with vision maintenance or some improvement in VA at
6 months [70].
Factors other than the drug may account for any
improvement observed after conversion, such as regression
to the mean and change over time [71]. A control group
continued on the originally assigned agent would help
evaluate how ‘treatment failures’ would do without
switching agents.
Duration of the initial loading phase on starting treatment
is important, as this may affect results achieved over time
[72]. Examination using ICGA is recommended in clear
nonresponders where PCV is suspected. Ophthalmologists
should retain the option of switching anti-VEGF agents for
nonresponders [73]. Switching therapies may also allow
clinicians to attempt to increase or extend the treatment
interval between injections once response is seen and the
disease stabilises. There is no uniform evidence of when to
switch; it may be early, usually after several injections or
late. It has been suggested that drug tolerance may play a
role in a subset of anti-VEGF refractory patients (persistent
ﬂuid on OCT despite monthly injections for ≥6 months)
who beneﬁt from a treatment switch [74].
Stopping treatment
Continuation of treatment is recommended if there is per-
sistent evidence of lesion activity, the lesion continues to
respond to repeated treatment and there are no contra-
indications to continuing treatment. Temporary cessation or
withholding of treatment may be considered if there is no
disease activity (disease has become inactive at ~6 to
12 months), stable disease activity despite frequent and
timely dosing and early review (i.e., at 2 weeks to conﬁrm a
lack of further response), or there has been one or more
adverse events related to drug or injection procedure and the
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clinician believes that treatment should be withheld. If there
is recurrence of CNV, treatment is reinstated until lesion
stabilisation is achieved, as indicated by best corrected
visual acuity and/or lesion morphology.
Amoaku et al. [64] recommended that ‘treatment should
not be discontinued before ﬁve consecutive injections have
been administered at the optimum recommended dosing
interval for the speciﬁc anti-VEGF agent, unless there is an
obvious deterioration of lesion morphology (poor response)
within this period‘. For cases of persistent, unchanged
accumulated macular ﬂuid after the loading phase, treatment
may be temporarily withheld and reinstated on signs of
active neovascularisation with increased ﬂuid on OCT [64].
Response to anti-VEGF treatment for nAMD is hetero-
geneous. Exclusively denoting treatment success early after
several initial intravitreal anti-VEGF injections may over-
look a subset of patients who experience a delayed response
with continued regular retreatment through 12 months [75].
A retrospective analysis of randomised controlled trial data
suggests there may be a subset of so-called delayed
responders, deﬁned as those who do not gain ≥15 letters
from baseline at month 3 but subsequently gained ≥15 let-
ters from baseline at month 12. These ﬁndings reinforce the
need to continue treatment in all patients including those
with a perceived suboptimal response, provided the patient
is gaining or maintaining the visual gains. Deﬁnitive treat-
ment success should be determined by the VA outcomes at
12 months rather than 3 months, argued Gale et al. [75].
A consensus approach to treatment decision making in
the long-term management of nAMD has been proposed by
UK retina specialists [28]. A trial of monitoring without
treatment may be considered for eyes with a dry macula and
stable vision on 4 consecutive 12-week visits on quarterly
anti-VEGF retreatment over 48 weeks. Patients completing
a further full year of monitoring without requiring injections
and who have no fellow eye involvement over this period
may then be considered for discharge from clinic, subject to
prompt reinstatement of treatment for disease recurrence or
reactivation.
Recurrence risk during maintenance phase and after
stopping treatment
The potential risk of reactivation of nAMD after stopping
anti-VEGF treatment warrants close consideration. Studies
point to a high rate of reactivation of nAMD over time after
disease stability has been achieved [76]. A database obser-
vational study of patients receiving anti-VEGF inhibitors
using a treat-and-extend protocol by Essex et al. [77] found
that the risk of reactivation reached 37.4% for those managed
on treatment intervals of ≥20 weeks. The same study reported
that 39% of eyes remained inactive at all observed visits
during the maintenance phase (deﬁned as starting at the ﬁrst
visit when the practitioner graded the neovascular lesion as
inactive) (minimum follow-up of 1 year, mean 945 days) [77].
Continued therapy at capped ﬁxed intervals once disease
stability has been achieved may help prevent long-term
recurrence in eyes with a good response on anti-VEGF
treatment [78].
Patients who have been discharged even after 1 year of
disease inactivity would beneﬁt from careful, long-term
follow-up. The duration of follow-up may be determined
through discussion between eye units and commissioners.
The UK AMD EMR Users Group evaluated time to
retreatment after a pause in anti-VEGF therapy for inter-
vals of 3 to 12 months in a large dataset of 12,951 eyes
from 14 clinic centres [49]. Recurrence risk diminished
the longer the treatment-free interval. After a treatment-
free interval of 12 months, 34% of these eyes required
retreatment after 12 months of follow-up. For all
treatment-free intervals, the mean VA at ﬁrst visit after
retreatment was lower than that at the beginning of the
treatment-free period, demonstrating that VA did not fully
recover on resumption of treatment [49].
Discharge from HES may be considered where local
pathways covering re-referral when necessary have been
agreed. Fast-track referral pathways should be in place at all
times to allow for prompt patient reassessment where there
are symptoms suggestive of recurrence or if reactivation is
diagnosed by an optometrist or doctor. Evidence is needed
on their effectiveness and false negative/false positive
referral rates.
Many retina specialists believe that nAMD patients are
never truly discharged, with ongoing review required using
low-risk clinics or monitoring by community optometrists.
Guidance from the College of Optometrists states that, in
the absence of clinical indications, optometrists should not
examine patients who are being monitored by the HES more
frequently than every 2 years [79]. This highlights the need
to determine how best to organise, staff and audit
community-based review programmes. The HES has a role
to play in ensuring the provision of adequate training and
support for community optometrists.
Improved surveillance strategies are needed. Some cen-
tres, for example, instruct discharged patients to telephone
the AMD service directly if they experience deterioration or
increased distortion of vision and are then triaged as new
patient referrals. A programme to allow for regular mon-
itoring of speciﬁc cohorts of patients with inactive nAMD
who meet local criteria for potential discharge may be
warranted, e.g., involving scheduled OCT monitoring—in
the community or HES—at 3-month intervals to screen for
reactivation before any signiﬁcant decrease of vision in
better-seeing eyes.
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Monitoring non-affected fellow eyes
The risk of developing late AMD in the second or fellow
eye is high, with almost half of eyes at risk requiring
bilateral treatment by 3 years [80, 81], and it is therefore
crucial to regularly monitor both eyes using OCT to ensure
the best visual prognosis. Involvement of the second eye
occurred after a median of 282 days, according to ﬁndings
from a retrospective EMR database study of patients
receiving anti-VEGF treatment for nAMD within a large
UK tertiary ophthalmic hospital [82].
In unilateral nAMD patients, the second eye is
usually the better-seeing eye
Extended follow-up intervals beyond 8 weeks for unilateral
nAMD patients receiving anti-VEGF therapy may adversely
affect VA at presentation of nAMD in the second eye,
which is usually the better-seeing eye [83] (Table 8).
Therefore, patients with unilateral nAMD whose follow-up
intervals are extended beyond 8 weeks on a treat-and-
extend treatment regimen might beneﬁt from OCT mon-
itoring at shorter intervals to prevent worse outcomes in
their second eye or from home monitoring.
Prompt intervention following earlier detection of second
eye involvement may improve clinical outcomes [84]. Second
treated eyes with nAMD often commence treatment with
better baseline VA and maintain better VA than ﬁrst treated
eyes [80]. It has been observed that fellow eye involvement
may inﬂuence the decision on retreatment interval when
managing disease reactivation during extension [28].
Home monitoring and regular eye tests
recommended
Currently in most places after discharge from hospital care,
nAMD patients self-monitor. Home monitoring, for exam-
ple using an Amsler chart (grid), can help identify subtle
changes in visual function that may suggest increasing
nAMD activity. McKibbin et al. [85] suggested that home
monitoring tasks—including measurement of near acuity
and assessments of environmental distortion and overall
visual function—are likely to remain complementary to
standard clinical assessment involving ETDRS distance
acuity, slit lamp examination and SD-OCT to determine
disease activity and retreatment need.
Faes et al. [86] concluded that both the Amsler grid and
preferential hyperacuity perimetry showed promising test
performance characteristics in ruling out nAMD in the
screening setting and could thus help in monitoring disease.
The vast majority of patients use a recording chart rather
than the conventional Amsler grid that comprises a high
contrast white grid on a black background, a fact that may
contribute to high false positive rates. Home monitoring
needs to be considered in the context of other supporting
local arrangements, such as fast-track community referral,
walk-in clinics or monitoring by high-street optometrists.
Future study results will provide further evidence
regarding the reliability of different tests for monitoring
disease progression and for early detection of fellow eye
involvement. The Monitoring for neovascular Age-related
macular degeneration Reactivation at Home (MONARCH)
study will assess whether three different home monitoring
vision tests performed by patients with nAMD can detect
reactivation of disease with comparable accuracy to routine
monitoring of nAMD activity status in HES clinics as part
of usual care [87]. Early Detection of Neovascular Age-
related macular degeneration (EDNA) is an ongoing UK
multicentre study evaluating different test strategies for
detecting fellow eye involvement during follow-up in sec-
ondary care of people with unilateral nAMD [88].
Similar to diabetic retinopathy screening, there may be a
role for screening those either at high risk for ﬁrst eye
involvement or for second eye involvement independently
of the follow-up interval when treating unilateral nAMD. A
health economic analysis needs to be undertaken to assess
the cost effectiveness of such an initiative.
Practicalities of injection delivery
Anti-VEGF intravitreal injection therapy is usually admi-
nistered in a dedicated clean room in an outpatient setting
Table 8 UK AMD EMR Users Group: multicentre results evaluating
effect of extended follow-up for unilateral nAMD on VA of second
initially unaffected eyes at the time of diagnosis of nAMD in the
contralateral eye [83]
OCT review interval for unilateral
nAMD
Risk of losing ≥3 lines of
VA in second eye
(between pre-diagnosis
and diagnosis)
OR (95% CI) P value
Sudden presentationa – –
≤4 Weeks 1.32 (0.82, 2.06) 0.24
>4 To ≤8 weeks 1.61 (1.23, 2.10) <0.001
>8 To ≤12 weeks 2.25 (1.50, 3.32) <0.001
>12 Weeks 3.47 (2.21, 5.37) <0.001
Adapted from Burton et al. [83] and reproduced with permission
CI conﬁdence interval, nAMD neovascular age-related macular
degeneration, OCT optical coherence tomography, OR odds ratio,
VA visual acuity
aSudden presentation group refers to those patients seen earlier than
their anticipated follow-up interval when the second eye was
diagnosed, presumed to have presented early due to worsening visual
symptoms in the second eye
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with full sterile precautions. It is important that there are
standards locally agreed with infection control in place to
govern intravitreal injection services in outpatient settings.
Guidance from the Royal College of Ophthalmologists
recommends that where ventilation to a dedicated clean
room has less than 10 air changes per hour, a local risk
assessment should be undertaken and agreed with the local
infection control team [89]. It is essential that cover is in
place to manage any urgent ophthalmological or medical
complications. It is advantageous to have nearby facilities
for slit lamp biomicroscopy/indirect ophthalmoscopy and
viewing retinal images. Resuscitation facilities, based on
local risk assessment, should be available in all settings
where intravitreal injection therapy is given.
An aseptic technique for intravitreal injection delivery is
required to minimise the risk of serious complications. Pro-
cedures should ensure adequate anaesthesia and asepsis,
including a broad-spectrum microbicide. Sterile gloves should
be worn following adequate hand antisepsis and face masks
are recommended. Routine use of a surgical drape is no longer
considered essential. However, an important principle is that
the eyelid margins should always be kept away from the
injection site to avoid contamination of the needle [89, 90].
At the pre-injection visit, patients should have a VA
measurement (preferably logarithm of the minimum angle
of resolution (logMAR)) and clinical evaluation. Immedi-
ately prior to the injection procedure, the correct patient
identity, correct eye and marking (where dictated by local
protocols), evidence of informed consent and the correct
drug to be injected must be conﬁrmed. Sedation may be
necessary in cases of severe needle phobia or anxiety.
The use of peri-injection antibiotics is no longer
recommended, as there is no evidence for prevention of
infection and repeated use of topical antibiotics has been
shown to increase the occurrence of antibiotic resistance
and potentially increased virulence [90, 91]. That said, the
local protocol governing administration of intravitreal
injection therapy should be adhered to.
It is reasonable to conduct bilateral injections subject to
observing appropriate procedures and precautions [52, 92].
When administering bilateral injections during the same
visit, each eye must be prepared separately and a different
batch of instruments must be used for each procedure. The
second injection should be treated as a separate procedure
within the same visit. A separate vial from a different batch
of the chosen medication is recommended for each eye.
Follow-up arrangements for repeat intravitreal injections
should be coordinated by a failsafe administrator to ensure
that all patients receive appointments and repeat injections
at the appropriate time.
To minimise the possibility of reactivation of CNV
postoperatively, most practitioners will schedule treatment
with intravitreal anti-VEGF injection for 1 to 2 weeks prior
to planned intraocular surgery. Recent study ﬁndings sug-
gest that cataract operation does not appear to increase the
recurrence of CNV in patients with nAMD or to have effect
on the time to recurrence and frequency of injections
required following surgery [93].
Special precaution is needed in patients with poorly
controlled glaucoma and injections should not be given
while the intraocular pressure (IOP) is ≥30 mmHg unless a
delay to achieve better pressure control would be sight-
threatening. Transient and sustained increases in IOP have
occasionally been observed after intravitreal injection pro-
cedures. The incidence of sustained elevation of IOP in
patients with nAMD reportedly varied from 3.45% to
11.6%, and few patients required surgical management to
control IOP [94]. The Diabetic Retinopathy Clinical
Research network noted that repeated intravitreal injections
of anti-VEGF therapy may increase the risk of sustained
IOP elevation or the need for ocular hypotensive treatment
in eyes with DMO and no prior open-angle glaucoma [95].
In cases known to have pressure spikes following intra-
vitreal injection, topical administration of iopidine 1% at 1 h
prior to anti-VEGF injection can help signiﬁcantly reduce
the magnitude of a post-injection elevation of the IOP [96].
Prophylactic treatment with oral acetazolamide may be
considered an option to minimise neuroretinal rim damage
in high-risk glaucoma patients who are most vulnerable to
IOP spikes and undergoing repeated injections of anti-
VEGF inhibitors [97]. Both IOP and the perfusion of the
optic nerve head should be monitored and managed
appropriately. In the event of a retinal break, intravitreal
treatment should be withheld and treatment should not be
resumed until the break is adequately repaired.
The beneﬁt–risk proﬁle of anti-VEGF treatment should be
discussed with the patient before initiating treatment and each
time the treatment regimen is altered. There is a theoretical
risk of arterial thromboembolic events (ATEs), including
stroke and myocardial infarction, following intravitreal use of
VEGF inhibitors [53, 54]. A low incidence rate of ATEs was
observed in the ranibizumab and aﬂibercept clinical trials in
patients with nAMD or other retinal vascular diseases, with
no major or notable differences observed when compared
with the respective comparator or control group [53, 54].
Nonetheless, practitioners suggest it is prudent to exercise
caution when treating patients who have had a recent heart
attack or stroke and discussion with the patient is advised.
Closing comments
Today, practitioners have greater experience and evidence
supporting what works best with respect to effective care and
service provision in the management of nAMD. Ongoing
treatment with intravitreal anti-VEGF therapy is required to
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maintain morphological recovery and long-term stabilisation
of visual function in most patients with active nAMD [4].
Hospital eye services have established a hybrid range of
initiatives and strategies to streamline service delivery and
maximise capacity, i.e., to enable prompt treatment of refer-
rals when indicated and maintenance of personalised follow-
up injection intervals to optimise efﬁcacy in the longer term.
Greater participation of non-medical health professionals
in the provision of routine retina care, often undertaking
tasks previously only performed by specialist doctors, has
proven an effective and safe service model with appropriate
training and governance that is led by ophthalmologists
specialising in retinal diseases. Imaging technologies have
improved dramatically, such that SD-OCT is increasingly
used for primary diagnosis, evaluation of treatment efﬁcacy
and long-term monitoring in the management of nAMD
[98]. This has allowed providers to implement multi-
disciplinary virtual assessment pathways.
Long-term treatment strategies have shifted from pre-
dominantly treatment as needed to proactive dosing strate-
gies, allowing greater use of capacity and ﬁnite resources.
Outcomes still vary between clinic centres and therefore
consistent standardised audit is recommended as a core
service standard, preferably using an integrated EMR sys-
tem. The issue of securing adequate funding remains para-
mount. Locally agreed metrics need to be agreed to identify
why or where additional potential funding may be required.
Greater consensus amongst ophthalmic retina specialists is
developing with regard to the core outcome standards
expected of a high-quality nAMD service.
In conclusion, the group’s suggested actions for delivering
high-quality care in the management of nAMD are focussed
on three main areas: maintain continuous proactive treatment
protocols and strategies to manage the increasing burden of
care while minimising monitoring visits; strengthen and
extend the skills and roles of non-medical AHPs to maximise
HES capacity and multidisciplinary competency to meet a
continuing increase in demand (face-to-face patient–con-
sultant consultations should take place at least every 6 to
12 months); and develop a long-term management protocol
for anti-VEGF maintenance therapy of nAMD, incorporating
expert guidance for monitoring without treatment, stopping
treatment and discharge decision making.
Medical retina services will continue to adapt and evolve
over time, based on sharing of best practice and continued
audit of clinical outcomes and service delivery performance.
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Eylea® 40 mg/ml solution for injection in a vial (aﬂi-
bercept) Prescribing Information
(Refer to full Summary of Product Characteristics
(SmPC) before prescribing)
Presentation: 1 ml solution for injection contains 40 mg
aﬂibercept. Each vial contains 100 microlitres, equivalent to
4 mg aﬂibercept. Indication(s): Treatment of neovascular
(wet) age- related macular degeneration (wAMD), macular
oedema secondary to retinal vein occlusion (branch RVO
or central RVO), visual impairment due to diabetic macular
oedema (DMO) in adults and visual impairment due to
myopic choroidal neovascularisation (myopic CNV).
Posology & method of administration: For intravitreal
injection only. Must be administered according to medical
standards and applicable guidelines by a qualiﬁed physician
experienced in administering intravitreal injections. Each
vial should only be used for the treatment of a single
eye. Extraction of multiple doses from a single vial may
increase the risk of contamination and subsequent infection.
The vial contains more than the recommended dose of
2 mg. The extractable volume of the vial (100 microlitres) is
not to be used in total. The excess volume should be
expelled before injecting. Refer to SmPC for full details.
Adults: The recommended dose is 2 mg aﬂibercept,
equivalent to 50 microlitres. For wAMD treatment is initi-
ated with 1 injection per month for 3 consecutive doses. The
treatment interval is then extended to 2 months. Based on
the physician’s judgement of visual and/or anatomic out-
comes, the treatment interval may be maintained at
2 months or further extended using a treat-and-extend
dosing regimen, where injection intervals are increased in 2-
or 4-weekly increments to maintain stable visual and/or
anatomic outcomes. If visual and/or anatomic outcomes
deteriorate, the treatment interval should be shortened
accordingly to a minimum of 2 months during the ﬁrst
12 months of treatment. There is no requirement for
monitoring between injections. Based on the physician’s
judgement the schedule of monitoring visits may be more
frequent than the injection visits. Treatment intervals greater
than 4 months between injections have not been studied.
For RVO (branch RVO or central RVO), after the initial
injection, treatment is given monthly at intervals not
shorter than 1 month. Discontinue if visual and anatomic
outcomes indicate that the patient is not beneﬁting from
continued treatment. Treat monthly until maximum visual
acuity and/or no signs of disease activity. Three or
more consecutive, monthly injections may be needed.
Treatment may then be continued with a treat-and-extend
regimen with gradually increased treatment intervals to
maintain stable visual and/or anatomic outcomes, however
there are insufﬁcient data to conclude on the length of these
intervals. Shorten treatment intervals if visual and/or ana-
tomic outcomes deteriorate. The monitoring and treatment
schedule should be determined by the treating physician
based on the individual patient’s response. For DMO,
initiate treatment with 1 injection/month for 5 consecutive
doses, followed by 1 injection every 2 months. No
requirement for monitoring between injections. After the
ﬁrst 12 months of treatment, and based on visual and/or
anatomic outcomes, the treatment interval may be extended
such as with a treat-and- extend dosing regimen, where the
treatment intervals are gradually increased to maintain
stable visual and/or anatomic outcomes; however there are
insufﬁcient data to conclude on the length of these intervals.
If visual and/or anatomic outcomes deteriorate, the treat-
ment interval should be shortened accordingly. The sche-
dule for monitoring should therefore be determined by the
treating physician and may be more frequent than the
schedule of injections. If visual and anatomic outcomes
indicate that the patient is not beneﬁting from continued
treatment, treatment should be discontinued. For myopic
CNV, a single injection is to be administered. Additional
doses may be administered if visual and/or anatomic out-
comes indicate that the disease persists. Recurrences should
be treated as a new manifestation of the disease. The
schedule for monitoring should be determined by the
treating physician. The interval between 2 doses should not
be shorter than 1 month. Hepatic and/or renal impairment:
No speciﬁc studies have been conducted. Available data do
not suggest a need for a dose adjustment. Elderly popula-
tion: No special considerations are needed. Limited
experience in those with DMO over 75 years old. Paedia-
tric population: No data available. Contraindications:
Hypersensitivity to active substance or any excipient; active
or suspected ocular or periocular infection; active severe
intraocular inﬂammation. Warnings & precautions: As
with other intravitreal therapies endophthalmitis, intraocular
inﬂammation, rhegmatogenous retinal detachment, retinal
tear and iatrogenic traumatic cataract have been reported.
Aseptic injection technique is essential. Patients should
be monitored during the week following the injection to
permit early treatment if an infection occurs. Patients must
report any symptoms of endophthalmitis or any of the
above mentioned events without delay. Increases in
intraocular pressure have been seen within 60 minutes of
intravitreal injection; special precaution is needed in
patients with poorly controlled glaucoma (do not inject
while the intraocular pressure is ≥ 30 mmHg). Immediately
after injection, monitor intraocular pressure and perfusion
of optic nerve head and manage appropriately. There is a
potential for immunogenicity as with other therapeutic
proteins; patients should report any signs or symptoms of
intraocular inﬂammation e.g pain, photophobia or redness,
which may be a clinical sign of hypersensitivity. Systemic
adverse events including non-ocular haemorrhages and
arterial thromboembolic events have been reported
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following intravitreal injection of vascular endothelial
growth factor (VEGF) inhibitors.
Safety and efﬁcacy of concurrent use in both eyes have
not been systemically studied. No data is available on
concomitant use of Eylea with other anti-VEGF medicinal
products (systemic or ocular). Caution in patients with risk
factors for development of retinal pigment epithelial tears
including large and/or high pigment epithelial retinal
detachment. Withhold treatment in patients with: rhegma-
togenous retinal detachment or stage 3 or 4 macular holes;
with retinal break and do not resume treatment until the
break is adequately repaired. Withhold treatment and do not
resume before next scheduled treatment if there is: decrease
in best-corrected visual acuity of ≥30 letters compared with
the last assessment; central foveal subretinal haemorrhage,
or haemorrhage ≥50%, of total lesion area. Do not treat in
the 28 days prior to or following performed or planned
intraocular surgery. Eylea should not be used in pregnancy
unless the potential beneﬁt outweighs the potential risk to
the foetus. Women of childbearing potential have to use
effective contraception during treatment and for at least
3 months after the last intravitreal injection. In patients
presenting with clinical signs of irreversible ischaemic
visual function loss, aﬂibercept treatment is not recom-
mended. Populations with limited data: There is limited
experience in DMO due to type I diabetes or in diabetic
patients with an HbA1c over 12% or with proliferative
diabetic retinopathy. Eylea has not been studied in patients
with active systemic infections, concurrent eye conditions
such as retinal detachment or macular hole, or in diabetic
patients with uncontrolled hypertension. This lack of
information should be considered when treating such
patients. In myopic CNV there is no experience with Eylea
in the treatment of non-Asian patients, patients who have
previously undergone treatment for myopic CNV, and
patients with extrafoveal lesions. Interactions: No avail-
able data. Fertility, pregnancy & lactation: Not recom-
mended during pregnancy unless potential beneﬁt
outweighs potential risk to the foetus. No data available in
pregnant women. Studies in animals have shown embryo-
foetal toxicity. Women of childbearing potential have to use
effective contraception during treatment and for at least
3 months after the last injection. Not recommended during
breastfeeding. Excretion in human milk: unknown. Male
and female fertility impairment seen in animal studies with
high systemic exposure not expected after ocular adminis-
tration with very low systemic exposure. Effects on ability
to drive and use machines: Possible temporary visual
disturbances. Patients should not drive or use machines if
vision inadequate. Undesirable effects: Very common:
Visual acuity reduced, conjunctival haemorrhage (wAMD
phase III studies: increased incidence in patients receiving
anti-thrombotic agents), eye pain. Common: retinal pigment
epithelial tear (known to be associated with wAMD;
observed in wAMD studies only), detachment of the retinal
pigment epithelium, retinal degeneration, vitreous haemor-
rhage, cataract (nuclear or subcapsular), corneal abrasion or
erosion, increased intraocular pressure, blurred vision,
vitreous ﬂoaters, vitreous detachment, injection site pain,
foreign body sensation in eyes, increased lacrimation, eyelid
oedema, injection site haemorrhage, punctate keratitis,
conjunctival or ocular hyperaemia. Serious: cf. CI/W&P - in
addition: blindness, culture positive and culture negative
endophthalmitis, cataract traumatic, transient increased
intraocular pressure, vitreous detachment, retinal detach-
ment or tear, hypersensitivity (during the post-marketing
period, reports of hypersensitivity included rash, pruritus,
urticaria, and isolated cases of severe anaphylactic/ana-
phylactoid reactions), vitreous haemorrhage, cortical catar-
act, lenticular opacities, corneal epithelium defect/erosion,
vitritis, uveitis, iritis, iridocyclitis, anterior chamber ﬂare,
arterial thromboembolic events (ATEs) are adverse events
potentially related to systemic VEGF inhibition. There is a
theoretical risk of arterial thromboembolic events, including
stroke and myocardial infarction, following intravitreal use
of VEGF inhibitors. As with all therapeutic proteins, there is
a potential for immunogenicity.
Consult the SmPC in relation to other side effects.
Overdose: Monitor intraocular pressure and treat if
required. Incompatibilities: Do not mix with other med-
icinal products. Special Precautions for Storage: Store in
a refrigerator (2°C to 8°C). Do not freeze. Unopened vials
may be stored at room temperature (below 25°C) for up to
24 hours before use. Legal Category: POM. Package
Quantities & Basic NHS Costs: Single vial pack £816.00.
MA Number(s): EU/1/12/797/002. Further information
available from: Bayer plc, 400 South Oak Way, Reading
RG2 6AD, United Kingdom. Telephone: 0118 206 3000.
Date of preparation: July 2018.
Eylea® is a trademark of the Bayer Group
Adverse events should be reported. Reporting forms
and information can be found at www.mhra.gov.uk/
yellowcard or search for MHRA Yellow Card in the
Google Play or Apple App Store.
Adverse events should also be reported to Bayer plc.
Tel.: 0118 2063500, Fax.: 0118 2063703, Email:
pvuk@bayer.com
Item Code: PP-EYL-GB-0246. Date of Preparation: May 2019.
Action on nAMD 21
This article was sponsored by Bayer plc. Prescribing information for Eylea® (aﬂibercept solution for injection) can be found on page 20 and 21 of this PDF.
